Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Abcellera Biologics Inc

ABCL
Current price
2.42 USD +0.05 USD (+2.11%)
Last closed 2.05 USD
ISIN CA00288U1066
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 616 835 136 USD
Yield for 12 month -38.11 %
1Y
3Y
5Y
10Y
15Y
ABCL
21.11.2021 - 28.11.2021

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its product pipeline includes ABCL635, an antibody-drug candidate, which is in preclinical trial to treat metabolic and endocrine conditions; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in preclinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; and partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada. Address: 150 West 4th Ave, Vancouver, BC, Canada, V5Y 1G6

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

11.86 USD

P/E ratio

Dividend Yield

Current Year

+28 833 000 USD

Last Year

+38 025 000 USD

Current Quarter

+5 050 000 USD

Last Quarter

+6 507 000 USD

Current Year

+28 833 000 USD

Last Year

+38 025 000 USD

Current Quarter

+5 050 000 USD

Last Quarter

-31 788 000 USD

Key Figures ABCL

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -223 916 992 USD
Operating Margin TTM -807.03 %
Price to Earnings
Return On Assets TTM -12.41 %
PEG Ratio
Return On Equity TTM -14.75 %
Wall Street Target Price 11.86 USD
Revenue TTM 28 833 000 USD
Book Value 3.57 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -45.00 %
Dividend Yield
Gross Profit TTM -138 426 000 USD
Earnings per share -0.55 USD
Diluted Eps TTM -0.55 USD
Most Recent Quarter IV 2024
Quarterly Earnings Growth YOY 45.90 %
Profit Margin

Dividend Analytics ABCL

Max Ratio

>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Dividend History ABCL

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Ex Dividend Date
Dividend CAGR 3Y
Dividend CAGR 5Y
Dividend CAGR 10Y
Consecutive Years
Consistent Years
Continuous Dividends
Forward Annual Dividend Yield
Forward Annual Dividend – USD
Last Split Factor
Payout Ratio
Last Split Date

Stock Valuation ABCL

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE 27.47
Enterprise Value Revenue 2.89
Price Sales TTM 21.39
Enterprise Value EBITDA 5.30
Price Book MRQ 0.61

Financials ABCL

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators ABCL

For 52 weeks

1.89 USD 4.34 USD
50 Day MA 2.64 USD
Shares Short Prior Month 22 787 356
200 Day MA 2.78 USD
Short Ratio 4.60
Shares Short 23 624 883
Short Percent 9.90 %